Question 1

What harms did the largest nesiritide trial record?

Accepted Answer

The ASCEND-HF trial is the heaviest evidence on this page, and its harm findings are mixed rather than alarming. Investigators randomly assigned 7141 patients who were hospitalized with acute heart failure to receive either nesiritide or placebo for 24 to 168 hours in addition to standard care. A placebo is an inactive infusion, so the comparison isolates nesiritide itself. There were no significant differences in rates of death from any cause at 30 days, at 3.6% with nesiritide against 4.0% with placebo. Worsening renal function, defined as more than a 25% fall in kidney filtration, ran at 31.4% against 29.5%, again not a significant gap. One harm did separate the groups. The authors wrote that nesiritide was associated with an increase in rates of hypotension, meaning low blood pressure. The trial was funded by Scios, the company that developed nesiritide, which a reader weighing these numbers is entitled to know.

Question 2

How often did blood pressure fall too far on nesiritide?

Accepted Answer

Often enough to count, and the drop carried weight of its own. A later analysis of ASCEND-HF found that 1555 of 7141 (21.8%) patients had an episode of hypotension, most of them without symptoms. Randomization to nesiritide was among the factors most strongly tied to it, at an odds ratio of 1.98, so roughly double the odds. That analysis then followed what happened next, and concluded that hypotension while hospitalized for acute decompensated heart failure is an independent risk factor for adverse 30-day outcomes. A fall in pressure, in other words, was more than a passing nuisance on a chart. Reviews from the approval era describe the same pattern at lower intensity. A 2007 review called dose-related hypotension the most frequently reported adverse effect, and a 2002 review gave symptomatic hypotension in 4% of patients at the recommended dose, against 5% on nitroglycerin.

Question 3

Does nesiritide harm the kidneys?

Accepted Answer

This was the question that turned nesiritide from a new drug into a contested one. A 2005 meta-analysis in Circulation drew on 5 randomized studies that included 1269 patients. It counted kidney function as worse when serum creatinine rose by more than 0.5 mg/dL. Creatinine is a waste product the kidneys clear, so a rising level signals slower filtering. The authors found that nesiritide significantly increases the risk of worsening renal function in these patients. They also said they could not tell whether that rise was harm to the kidney or a shift in blood flow and pressure. A shift in flow can lift creatinine without any damage to kidney tissue. A 2007 safety review leaned that way, calling the rise a response to lost fluid, wider blood vessels and damped stress hormones. ASCEND-HF later found nesiritide was not tied to worse kidney function in its patients. How the risk shifted with the amount given is broken down on the Natriuretic peptide dosage page.

Question 4

Did nesiritide raise the risk of dying?

Accepted Answer

The early alarm said it might, and the larger evidence that followed did not bear that out. A 2009 review recounts that in 2005, suspicions arose that nesiritide may worsen renal function and increase the risk of short term mortality. A 2006 meta-analysis of seven randomised trials then concluded that nesiritide is not associated with a higher 30- or 180-day mortality, while calling for trials powered to settle the point. A 2016 meta-analysis of 22 trials and 38,064 patients found non-significant differences in short-term mortality, at a relative risk of 1.24 with a confidence interval from 0.85 to 1.80. A relative risk above 1 leans toward harm, but an interval that crosses 1 cannot exclude no effect at all. The same 2016 analysis of trial patients did report that nesiritide increased the risk of cardiovascular adverse events. Death and harm are separate questions, and on this record the first looks neutral while the second does not.

Question 5

Does nesiritide disturb the heart's rhythm?

Accepted Answer

Against the medicine it was most often compared with, it looked steadier. The PRECEDENT trial took 255 patients in hospital with heart failure. It gave them one of two doses of nesiritide or dobutamine, a medicine that drives the heart harder. Heart rhythm was recorded on 24-hour monitors before and during the drip. Dobutamine raised the number of runs of fast beats from the lower chambers. With nesiritide, the authors wrote, extra beats either fell or did not change. That comparison is with a medicine known to provoke rhythm problems. So it shows nesiritide was the gentler of the two, not that it was free of rhythm effects. In the VMAC trial, the common events in the first 24 hours on nesiritide or nitroglycerin still included short runs of fast beats and angina, which is chest pain from strained heart muscle.

Question 6

What did the carperitide studies record?

Accepted Answer

Carperitide is an A-type natriuretic peptide used mainly in Japan, and its record is smaller and harder to read. A 2025 meta-analysis pooled four randomised trials and five propensity-matched studies of carperitide in acute heart failure, with in-hospital death as its main outcome. Propensity-matched studies are observational, pairing treated patients with similar untreated ones rather than assigning them at random. Pooling all nine, the death rate in hospital was higher with carperitide, at an odds ratio of 1.38 with I2 = 77%. That I2 figure shows the studies disagreed strongly with each other. Across the four randomised trials alone, the 2025 analysis found no significant difference in in-hospital mortality, with I2 = 39%. That result's interval ran from 0.07 to 10.49, too wide to rule harm in or out. It reported no significant differences observed between the two groups in terms of incidence of hypotension. So the carperitide harm signal comes mainly from observational data, and the randomised data are too small to confirm or dismiss it.

Question 7

Can natriuretic peptides themselves do harm in the body?

Accepted Answer

In mice and in heart cells, there is one finding that says they can contribute to harm under stress. A 2020 study used a hypertensive mouse model and stretched atrial heart cells to test whether reactive fats formed by oxidative damage drive atrial fibrillation, an irregular rhythm of the upper chambers. In those mice and cells it found natriuretic peptides generated cytotoxic oligomers, a process accelerated by those reactive fats, contributing to the build-up of protein clumps in the atria. Cytotoxic means toxic to cells, and an oligomer is a small clump of protein molecules stuck together. Read that carefully. The peptides in that work were the animals' own, made by strained hearts, and nobody was given anything extra. It is a mechanism in mice, and it does not tell anyone what a hospital drip of nesiritide or carperitide does to a human heart.

Question 8

Is the reading used to catch heart harm from other medicines?

Accepted Answer

Yes, and this is where natriuretic peptides do most of their safety work: as an alarm rather than as the thing given. A 2019 review on cancer care opens with the problem, saying cardiovascular effects of cancer therapies are of concern, and that prediction, diagnosis, and management of cardiotoxicity is a challenge. It concludes that biomarkers can be incorporated into a detection strategy for cardiotoxicity, meaning heart damage caused by a therapy. How late that harm can surface shows in the title of a 2020 report, Acute Heart Failure 29 Years After Treatment for Childhood Cancer. Animal work uses the same alarm, and a 2026 study is titled Idebenone protects against doxorubicin-induced cardiac injury, which is heart damage caused by the medicine doxorubicin. In each of these the reading reports on harm done by something else. A rising figure in someone on chemotherapy is a warning about the chemotherapy.

Question 9

What does a natriuretic peptide interact with?

Accepted Answer

Two interactions appear in these sources, one with the medicine and one with the blood test. For the medicine, a 2005 review of heart surgery anaesthesia notes that intraoperatively the doses of nesiritide and anesthetics must be adjusted because of a potential interaction. The review summary does not set out the mechanism, so that is a caution to adjust rather than a measured effect. The blood test has its own catch. The 2018 review explains that neprilysin, an enzyme that breaks BNP down, is blocked by one class of heart failure medicine, and that this may present a challenge in the interpretation of levels of BNP. Its answer is to measure the other half of the molecule, since use of NT-proBNP measurement has been suggested with that class because its concentrations are not affected by neprilysin inhibition. On one of these medicines a BNP figure can read higher because less of it is being broken down, while the NT-proBNP figure is not shifted that way.

Question 10

Who was left out of the studies?

Accepted Answer

The large nesiritide trial took adults admitted to hospital with acute heart failure, and the groups outside that frame are thinly covered. A 2020 Cochrane review of heart failure treatment in people with chronic kidney disease found that in acute heart failure the effects of nesiritide on death, kidney function and hypotension were uncertain due to sparse data or were not reported. Approximately half of people with heart failure have chronic kidney disease, the same review notes, so that is a large gap rather than a corner case. Children appear in one retrospective analysis of 26 patients with critical congenital heart disease, given 37 infusions in a cardiac intensive care unit, which found no worsening of renal function. Looking back at records, with each child measured only against their own state before the infusion, can describe what happened but cannot establish safety. For carperitide, the summary behind this page does not list entry rules, so who was left out of those studies cannot be stated.

Question 11

Is nesiritide approved, and what does that cover?

Accepted Answer

Nesiritide was approved and launched in the US in August 2001, for intravenous treatment of patients with acute decompensated heart failure who have dyspnea at rest or at minimal activity. Dyspnea is breathlessness. A 2008 review records that Health Canada had also approved it for the same group of patients. The 2011 ASCEND-HF authors, writing after their own result, said nesiritide cannot be recommended for routine use in the broad population of patients with acute heart failure. Approval and routine use are different things, and these sources record both. Carperitide is used intravenously, primarily in Japan, and the summary behind this page does not describe its approval status. Whatever standing either drug has belongs to that hospital product, given by drip to admitted patients under monitoring. It does not travel to a vial sold outside a hospital, which inherits nothing from either record.

Question 12

Does a research-grade vial carry risks the hospital form does not?

Accepted Answer

None of the research behind this page concerns a natriuretic peptide sold as a research compound, so its purity, strength and sterility are unmeasured in these sources. The hospital forms are given through a vein by staff watching blood pressure and heart rhythm, and even under those conditions low blood pressure was the harm the large nesiritide trial recorded most clearly. A vial outside that setting removes the monitoring that would catch it. That is the editorial point rather than a finding: the risks that matter most for an unlabelled vial are the ones no study behind this page was designed to measure, and that is a gap, not a reassurance.

Question 13

Why did nesiritide's safety stay disputed for so long?

Accepted Answer

Because the warning came from pooled small trials, and the trial big enough to answer it took years to run. A 2009 review of the patient trials notes that meta-analyses suggesting increased mortality and renal dysfunction after nesiritide use were published 4 - 5 years after its introduction in the US. These reports prompted new recommendations on nesiritide use by an expert panel, the same review adds. A 2007 reappraisal said a large outcomes trial in patients with ADHF would help clarify the role of nesiritide. ASCEND-HF became that trial, and nesiritide was not associated with an increase or a decrease in the rate of death and rehospitalization. An editorial in the same journal carried the title The lost decade of nesiritide. What the trials counted as benefit, including the breathlessness result, is weighed on the Natriuretic peptide benefits page.

Natriuretic peptide side effects and safety data